Content Block Tag: NRG-CC004

‘Text/HTML’ of page ‘NRG-CC004’

DOWNLOAD OR PRINT THE PDF OF THIS STUDY RESULTS SUMMARY

‘List of publications with references that were generated from this study’ of page ‘NRG-CC004’

Barton DL, Pugh SL, Ganz PA, Plaxe SC, Koontz BF, Carter J, Greyz-Yusupov N, Page SJ, Rowland KM Jr, Balcueva EP, Nabeel S, Basil JB, Hill ML, Muller CY, Bell MC, Deshmukh S, Kachnic LA. Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: […]

‘Who can I contact for further information? ‘ of page ‘NRG-CC004’

Please talk with your doctor about any questions or concerns you may have about this summary. Further details about the design, conduct and results of this study are available at www.clinicaltrials.gov.

‘What did the researchers learn that will be helpful to other people with this condition?’ of page ‘NRG-CC004’

Based on the study results, there is not much we can recommend in terms of desire.However, it was important that in this study, over 90% of the women who participated had vulvo-vaginal dryness or pain with intercourse that was moderate to severe.This could have been a barrier in evaluating bupropion for desire because vulvo-vaginal health […]

‘Are there any steps that may need to be taken at this time or in the future for those who participated in the study?’ of page ‘NRG-CC004’

For participants in this study, there are no immediate or long-term steps that need to be considered because of these findings. All participants in this study have completed their treatment and should be followed by their doctor. 

‘What were the major findings of the study?’ of page ‘NRG-CC004’

Two hundred thirty women were randomly assigned from 72 institutions through the NRG Oncology network. Bupropion was not more effective than placebo in improving sexual desire. There were no significant differences between groups in change of the desire subscale scores of the Female Sexual Function Index, a very well-respected scale measuring sexual function.   Participants in […]

‘What did the study involve?’ of page ‘NRG-CC004’

After enrolling on this study, participants were randomized to one of three study groups. Two different doses of bupropion, 150 mg extended release (XL) and 300 mg extended release (XL), were compared to a placebo.

‘Background of the study’ of page ‘NRG-CC004’

This study addressed the common side effect of decreased sexual health in women who have been treated for breast or gynecologic cancer. The study tested whether bupropion, a medication that is approved for depression and smoking cessation, can improve sexual desire compared to placebo. 

‘Text/HTML’ of page ‘NRG-CC004’

‘Introduction’ of page ‘NRG-CC004’

rod